Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020
Biohaven Pharmaceutical (NYSE: BHVN) will report its second quarter 2020 financial results on August 10, 2020, at 8:00 a.m. ET. The earnings call will review the company's recent accomplishments and anticipated milestones, including its innovative therapies targeting neurological and neuropsychiatric diseases. Biohaven is known for its FDA-approved treatment, NURTEC™ ODT, for migraines and has a broad pipeline focused on various conditions. Interested parties can access the call via phone or through the company's website.
- Biohaven has a portfolio of innovative therapies targeting neurological and neuropsychiatric diseases.
- FDA-approved NURTEC™ ODT for migraine treatment demonstrates successful product development.
- Upcoming earnings call indicates ongoing communication with investors and transparency about business operations.
- None.
NEW HAVEN, Conn., Aug. 5, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming second quarter 2020 earnings call and webcast, reporting financial results for the quarter ended June 30, 2020 and providing a review of recent accomplishments and anticipated upcoming milestones, on Monday, August 10, 2020 at 8:00 a.m. ET.
To access the call, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast, and accompanying slide presentation, can be accessed through the "Investors" section of Biohaven's website at www.biohavenpharma.com . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the call will be made available for two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (domestic) or 201-612-7415 (international) with conference ID 13707340. An archived webcast will be available on Biohaven's website.
About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.
Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
NURTEC is a trademark of Biohaven Pharmaceutical Holding Company Ltd.
View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-pharmaceutical-to-report-second-quarter-2020-financial-results-and-recent-business-developments-on-august-10-2020-301106892.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.
FAQ
When will Biohaven Pharmaceutical report its second quarter 2020 financial results?
What is the conference call number for Biohaven's earnings report?
What products are included in Biohaven's portfolio?
How can I access the Biohaven earnings call webcast?
